Insulet Corporation (PODD) Research

Forward Estimates

EPS Estimates

Current Qtr

$1.45

$1.36$1.55

vs $1.17+24.0%

20 analysts

Next Qtr

$1.64

$1.54$1.73

vs $1.24+32.2%

20 analysts

Current Yr

$6.48

$6.37$6.59

vs $4.97+30.4%

22 analysts

Next Yr

$8.09

$7.58$8.38

vs $6.48+24.8%

22 analysts

Revenue Estimates

Current Qtr

$787.82M

$784.00M$792.83M

vs $649.10M+21.4%

21 analysts

Next Qtr

$846.65M

$829.80M$868.70M

vs $706.30M+19.9%

21 analysts

Current Yr

$3.32B

$3.21B$3.36B

vs $2.71B+22.7%

24 analysts

Next Yr

$3.94B

$3.74B$4.06B

vs $3.32B+18.6%

24 analysts

SEC filings →

View all 10-K, 10-Q, and 8-K filings for PODD on EDGAR.

PODD filing events and research context
Filed	Item	Context
Feb 18, 2026	business	Insulet Corporation specializes in tubeless, continuous insulin delivery systems for insulin-dependent diabetes. Its flagship product, the Omnipod 5 Automated Insulin Delivery System, integrates with third-party continuous glucose monitors from Dexcom and Abbott to automatically adjust insulin dosing. The company also markets the Omnipod DASH and is phasing out the Classic Omnipod. Insulet targets the conversion of multiple daily injection (MDI) users to pump therapy across Type 1 and insulin-requiring Type 2 diabetes markets, recently expanding the Omnipod 5 indication to include Type 2 adults. Future growth drivers include the development of Omnipod 6 and a fully closed-loop system for Type 2 diabetes. Revenue is highly concentrated, with three distributors accounting for approximately 74% of total sales in 2025. Operational risks include reliance on sole-sourced specialized chips and stringent FDA and EU MDR regulatory requirements. Additionally, the increasing adoption of GLP-1 drugs may delay the progression of Type 2 diabetes, potentially impacting the addressable market. Manufacturing is scaled across facilities in the U.S., Malaysia, and a new plant in Costa Rica. The company also generates ancillary revenue by producing pods for Amgen’s Neulasta Onpro kit.
Feb 18, 2026	mda	Total revenue grew 30.7% to $2.71 billion in 2025, driven by the global rollout of the Omnipod 5 automated insulin delivery system. U.S. revenue increased 27.2% to $1.92 billion, while international revenue surged 44.1% to $754.3 million as the platform expanded to 19 countries. Gross margin improved to 71.6% due to manufacturing efficiencies and higher average selling prices. The company is prioritizing Omnipod 5 for the type 2 diabetes market, leading to the cancellation of the Omnipod GO project and a $13.5 million inventory charge. Future growth drivers include the development of Omnipod 6, integration with Abbott’s FreeStyle Libre 3 Plus, and expanded manufacturing capacity in Malaysia and Costa Rica. Adjusted EBITDA rose to $645.5 million, and free cash flow reached $377.7 million. Capital activities included the repurchase of convertible senior notes, resulting in a $123.9 million extinguishment loss, and the issuance of 6.5% senior unsecured notes. Key risks include potential material impacts from the elimination of medical device tariff exemptions and the implementation of OECD Pillar Two global minimum tax. A $59.4 million legal award against EOFlow remains pending appeal.
Feb 18, 2026	risk_factors	Insulet Corporation faces significant operational risks centered on its Omnipod platform, specifically Omnipod 5 and DASH. A critical vulnerability is the company's reliance on single-source external suppliers for semiconductor chips, where disruptions could lead to manufacturing delays or lost sales. Revenue is highly concentrated, with three primary distributors accounting for approximately 78% of total sales. Additionally, the company is exposed to foreign currency volatility, as 28% of its revenue is denominated in currencies including the Euro, British pound, Malaysian ringgit, and Mexican peso. Financial risks include variable-rate debt under its Term Loan B, partially mitigated by $460 million in interest rate swaps. Legal risks persist regarding the misappropriation of trade secrets by EOFlow; while a judgment was awarded, the final recovery remains uncertain due to ongoing appeals. Furthermore, the company manages complex variable consideration risks related to rebates for managed care organizations and pharmacy benefit managers in the U.S. market. Finally, the Drug Delivery segment is heavily dependent on a single customer, Amgen, for the Neulasta Onpro kit.

Filed

Item

Context

Feb 18, 2026

business

Insulet Corporation specializes in tubeless, continuous insulin delivery systems for insulin-dependent diabetes. Its flagship product, the Omnipod 5 Automated Insulin Delivery System, integrates with third-party continuous glucose monitors from Dexcom and Abbott to automatically adjust insulin dosing. The company also markets the Omnipod DASH and is phasing out the Classic Omnipod. Insulet targets the conversion of multiple daily injection (MDI) users to pump therapy across Type 1 and insulin-requiring Type 2 diabetes markets, recently expanding the Omnipod 5 indication to include Type 2 adults. Future growth drivers include the development of Omnipod 6 and a fully closed-loop system for Type 2 diabetes. Revenue is highly concentrated, with three distributors accounting for approximately 74% of total sales in 2025. Operational risks include reliance on sole-sourced specialized chips and stringent FDA and EU MDR regulatory requirements. Additionally, the increasing adoption of GLP-1 drugs may delay the progression of Type 2 diabetes, potentially impacting the addressable market. Manufacturing is scaled across facilities in the U.S., Malaysia, and a new plant in Costa Rica. The company also generates ancillary revenue by producing pods for Amgen’s Neulasta Onpro kit.

Feb 18, 2026

mda

Total revenue grew 30.7% to $2.71 billion in 2025, driven by the global rollout of the Omnipod 5 automated insulin delivery system. U.S. revenue increased 27.2% to $1.92 billion, while international revenue surged 44.1% to $754.3 million as the platform expanded to 19 countries. Gross margin improved to 71.6% due to manufacturing efficiencies and higher average selling prices. The company is prioritizing Omnipod 5 for the type 2 diabetes market, leading to the cancellation of the Omnipod GO project and a $13.5 million inventory charge. Future growth drivers include the development of Omnipod 6, integration with Abbott’s FreeStyle Libre 3 Plus, and expanded manufacturing capacity in Malaysia and Costa Rica. Adjusted EBITDA rose to $645.5 million, and free cash flow reached $377.7 million. Capital activities included the repurchase of convertible senior notes, resulting in a $123.9 million extinguishment loss, and the issuance of 6.5% senior unsecured notes. Key risks include potential material impacts from the elimination of medical device tariff exemptions and the implementation of OECD Pillar Two global minimum tax. A $59.4 million legal award against EOFlow remains pending appeal.

Feb 18, 2026

risk_factors

Insulet Corporation faces significant operational risks centered on its Omnipod platform, specifically Omnipod 5 and DASH. A critical vulnerability is the company's reliance on single-source external suppliers for semiconductor chips, where disruptions could lead to manufacturing delays or lost sales. Revenue is highly concentrated, with three primary distributors accounting for approximately 78% of total sales. Additionally, the company is exposed to foreign currency volatility, as 28% of its revenue is denominated in currencies including the Euro, British pound, Malaysian ringgit, and Mexican peso. Financial risks include variable-rate debt under its Term Loan B, partially mitigated by $460 million in interest rate swaps. Legal risks persist regarding the misappropriation of trade secrets by EOFlow; while a judgment was awarded, the final recovery remains uncertain due to ongoing appeals. Furthermore, the company manages complex variable consideration risks related to rebates for managed care organizations and pharmacy benefit managers in the U.S. market. Finally, the Drug Delivery segment is heavily dependent on a single customer, Amgen, for the Neulasta Onpro kit.

Forward Estimates

PODD filing events and research context

Keep researching PODD

Related tickers

Related explainers

Forward Estimates